RECPIPE



23448

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FEB 2 2 2001

re United States Application of:

Applicant:

KÜPPER, et al.

Attorney Docket No.:

4121-115

Application No.:

09/446,808

Group Art Unit

1643

Date Filed:

July 21, 2000

Title:

MAMMAL WITH INHIBITION OF THE POLY (ADP RIBOSE)

POLYMERASE AND METHOD

FOR USING SAME TO IDENTIFY CANCERIGENIC

AGENTS

FIRST CLASS MAIL CERTIFICATE

I hereby certify that I am mailing the attached documents to the Commissioner for Trademarks on the date specified, in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 and First Class Mailed under the provisions of 37 CFR 1.8.

Lynda Montova

February 19, 2001
Date of Mailing

-

REQUEST FOR CORRECTED FILING RECEIPT IN U.S. PATENT APPLICATION NO. 09/446,808

Commissioner for Patents Washington, D.C. 20231

Sir:

A review of the Filing Receipt in the above-identified U.S. patent application, as received in the undersigned attorney's office, has revealed the presence of several errors, typographical errors in the Applicant's names as well as the title of the application.

Please make the above-defined necessary changes to the Filing Receipt and issue a Corrected Filing Receipt. A copy of the Filing Receipt, with the corrections noted in red ink, is enclosed herewith.



INTELLECTUAL PROPERTY/

TECHNOLOGY LAW
P. O. Box 14329
Research Triangle Park, NC 27709
(919) 419-9350 - phone
(919) 419-9354 - fax Attorney File: 4121-115

Respectfully submitted,

Steven J. Hultquist

Registration No. 28,021 Attorney for Applicant

United States Patent and Trademark Office COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov TOT CLAIMS IND CLAIMS FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS GRP ART UNIT CATION NUMBER FILING DATE 07/21/2000 446.808 1643 FEB 2 2 2001 **FILING RECEIPT** Steven J Hultquist MADEN DO Box 14329 OC000000005730893* Research Triangle Park, NC 27709 Date Mailed: 02/02/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Jan-Heiner Kupper, Kusterdingen, GERMANY;
Alexander Bürkle, Newcastle Upon Tyne, UNITED KINGDOM;
Leon Van Gool, Arnhem, NETHERLANDS;
Harald, Hausen, Waldmichelbach, GERMANY;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A 371 OF PCT/DE98/01797 06/24/1999

Foreign Applications

GERMANY 197 26 824.2 06/24/1997

** SMALL ENTITY **

Title

Method for identifying cancerlyenic agents using a mammal with inhibition of the poly(adp. ribose) polymerase Mammal with Inhibition of the Poly (ADP Ribose) Polymerase and Method for Using Same to Identity Cancerigenic Preliminary Class Agents

435



LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Data entry by : NGUYEN, SON Team : OIPE Date: 02/02/2001



Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231





United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

Bib Data Sheet

CONFIRMATION NO. 2937

Jan-Heiner Kupper, Kusterdingen, GERMANY; Alexander Burkle, Newcastle Upon Tyne, UNITED KINGDOM; Leon Van Gool, Arnhem, NETHERLANDS; Harald Zur Hausen, Waldmichelbach, GERMANY; **CONTINUING DATA **********************************							
Jan-Heiner Kupper, Kusterdingen, GERMANY; Alexander Burkle, Newcastle Upon Tyne, UNITED KINGDOM; Leon Van Gool, Arnhem, NETHERLANDS; Harald Zur Hausen, Waldmichelbach, GERMANY; **CONTINUING DATA **********************************		· 07/21/2000	CLASS	l .		DOCKET NO.	
FILING FEE RECEIVED 615 FILING FEE RECEIVED 6	Alexander Bu Leon Van Go Harald Zur Ha * CONTINUING DA THIS APPLIC	rkle, Newcastle Upon Tyol, Arnhem, NETHERLA ausen, Waldmichelbach, ATA **********************************	yne, UNITED KINGD NDS; , GERMANY;			JUN 2 7	200
SUSC 119 (a-d) conditions yes no Met after Allowance Examiner's Signature Initials STATE OR COUNTRY GERMANY 1 CLAIMS CLAIMS 1 CLAIMS 1 CLAIMS 1 CLAIMS CLAIMS 1 CLAIMS CLAIMS 1 CLAIMS CLAIMS 1 CLAIMS 1			** SMALL	ENTITY **		<u> </u>	
AMMAL WITH INHIBITION OF THE POLY(ADP RIBOSE) POLYMERASE AND METHOD FOR USING AME TO IDENTIFY CANCERIGENIC AGENTS FILING FEE RECEIVED 615 FEES: Authority has been given in Paper to charge/credit DEPOSIT ACCOUNT No to charge/credit DEPOSIT ACCOUNT	net /erified and	s yes no Met after Allowance	country GERMANY	DRAWING	CLAIR		NT
FILING FEE RECEIVED 615 FILING FEE RECEIVED 615 FILING FEE RECEIVED 615 FEES: Authority has been given in Paper No to charge/credit DEPOSIT ACCOUNT for following: All Fees 1.16 Fees (Filing) 1.17 Fees (Processing Ext. of time) 1.18 Fees (Issue) Other	23448						_
	FILING FEE FEE	Y CANCERIGENIC AGE ES: Authority has been g to charge/cr	ENTS given in Paper redit DEPOSIT ACCO	DUNT In AI	I Fees 16 Fees (17 Fees (18 Fees (Filing) Processing Ext. o	